Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in, Europe; Mocroft, A; Reiss, P; Kirk, O; Mussini, C; Girardi, E; Morlat, P; Stephan, C; De Wit, S; Doerholt, K; Ghosn, J; Bucher, Hc; Lundgren, Jd; Chene, G; Miro, Jm; Furrer H., Collaborators: Weller I; Costagliola, D; Ledergerber, B; Lundgren, J; Grarup, J; Chene, G; Touloumi, G; Warszawski, J; Meyer, L; Dabis, F; Krause, Mm; Ghosn, J; Leport, C; de Wolf, F; Reiss, P; Porter, K; Dorrucci, M; Sabin, C; Gibb, D; Fätkenheuer, G; Del Amo, J; Obel, N; Thorne, C; Mocroft, A; Kirk, O; Stephan, C; Pérez Hoyos, S; Antinori, A; d'Arminio Monforte, A; Tovo, Pa; de Martino, M; Brockmeyer, Nh; Ramos, J; Battegay, M; Mussini, C; Carnicer, D; Tookey, P; Casbona, J; Miró, Jm; Castagna, A; de Wit, S; Torti, Carlo; Teira, R; Garrido, M; Bucher, H; Dabis, F; Egger, M; Furer, H; Kirk, O; Lewden, C; Miro, Jm; Mocroft, A; Newell, Ml; Phillips, A; Sabin, C; Stearne, J; Telenti, A; Collin Filleul, F; Ellefson, M; Fabre Colin, C; Kjaer, J; Schwimmer, C; Paulsen, M; Dedes, N.